So we have 668m shares on issue.
Cash is approximately A$18m.
At 9c we have a market cap of A$60mAt AUD/USD at 62c, this equates to an enterprise value of US$26m
After the results across DMD, Limb Girdle, Long Covid, the potential of the combination studies, the high likelihood of our P2b being an approve able trial, witnessing Sarepta sales of >US$200m for the QUARTER for drugs that show no clinical efficacy..
The low valuation of this company is a disgrace.
I would love to know lots of different peoples opinions on what key catalysts will improve the outlook for the share price?
Thanks in Advance.
- Forums
- ASX - By Stock
- PER
- ANP Value
ANP Value
-
-
- There are more pages in this discussion • 328 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PER (ASX) to my watchlist
|
|||||
Last
8.5¢ |
Change
-0.002(2.30%) |
Mkt cap ! $76.63M |
Open | High | Low | Value | Volume |
8.7¢ | 8.7¢ | 8.3¢ | $82.04K | 969.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 200841 | 8.3¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
8.5¢ | 102187 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 217841 | 0.083 |
2 | 143500 | 0.081 |
2 | 106250 | 0.080 |
3 | 132078 | 0.079 |
2 | 120924 | 0.078 |
Price($) | Vol. | No. |
---|---|---|
0.085 | 102187 | 2 |
0.087 | 429525 | 2 |
0.088 | 457142 | 2 |
0.089 | 295000 | 3 |
0.090 | 494374 | 5 |
Last trade - 16.10pm 02/09/2024 (20 minute delay) ? |
Featured News
PER (ASX) Chart |